What are the treatment options for severe chronic rhinosinusitis?

Treatment Options for Severe Chronic Rhinosinusitis

For severe chronic rhinosinusitis, treatment should be tailored to disease subtype rather than following a one-size-fits-all approach, with options including appropriate medical therapy (nasal saline irrigations, intranasal corticosteroids, oral corticosteroids, and antibiotics when purulent discharge is present), biologics for CRS with nasal polyps, and endoscopic sinus surgery for patients who fail medical management or have specific disease characteristics like polyps with bony erosion, eosinophilic mucin, or fungal balls 1.

Medical Management Framework

First-Line Medical Therapy

The cornerstone of medical management includes:

• Nasal saline irrigations - reduces inflammatory burden and improves mucus clearance 1, 2
• Intranasal corticosteroids (INCS) - strong evidence supports their use across all CRS subtypes 1, 3, 2
• Oral corticosteroids - can reduce inflammation and symptoms, though side effect profile must be considered 1

When to Use Antibiotics

Antibiotics should NOT be prescribed unless significant or persistent purulent nasal discharge (anterior, posterior, or both) is present on examination 1. This is a strong recommendation that prevents unnecessary antibiotic exposure and associated harms.

Important Caveat on Medical Therapy Duration

The 2025 AAO-HNS guidelines explicitly reject the concept of "maximal medical therapy" as a prerequisite for surgery 1. Decisions about specific medications and duration should be determined by disease subtype, tolerability, and expected effectiveness - not arbitrary time periods. Continuing ineffective medical therapy can cause harm through medication side effects, costs, and delayed definitive treatment.

Biologic Therapy for CRS with Nasal Polyps

Available Biologics

For severe CRS with nasal polyps (CRSwNP), particularly with Type-2 inflammation, three biologics are approved:

• Dupilumab (IL-4/IL-13 inhibitor)
• Omalizumab (anti-IgE)
• Mepolizumab (anti-IL-5)

These agents demonstrate significant reductions in nasal polyp burden, SNOT-22 scores, and improved olfactory function 3, 4, 5.

When to Consider Biologics

Biologics are particularly appropriate for patients with:

• Severe CRSwNP with Type-2 inflammation
• Comorbid asthma, atopic dermatitis, or eosinophilic esophagitis
• Corticosteroid-dependent disease
• High recurrence rates after surgery
• NSAID-exacerbated respiratory disease (NERD/AERD) 3, 2, 6

Critical limitation: Biologics address inflammation but not anatomical obstruction, and concerns about long-term safety, cost, and accessibility remain 5, 7.

Surgical Management

Who Benefits Most from Surgery

Surgery should be offered when anticipated benefits exceed nonsurgical management alone, particularly for patients with 1:

• CRS with nasal polyps
• Polyps with bony erosion
• Eosinophilic mucin
• Fungal balls
• Failed appropriate medical therapy

Surgical Planning Requirements

Before surgery:

• Obtain fine-cut CT scan for surgical planning if not already available 1
• Do NOT plan surgery extent solely based on arbitrary CT criteria (minimal mucosal thickening, sinus opacification, or outflow obstruction) 1
• For disease involving polyps, osteitis, bony erosion, or fungal disease: perform full exposure of sinus cavity with diseased tissue removal, not just balloon or manual ostial dilation 1

Postoperative Expectations

Patients must understand:

• Potential for chronicity or relapse
• Likelihood of long-term medical management even after surgery
• Need for follow-up between 3-12 months post-surgery with symptom assessment and nasal endoscopy 1

Algorithm for Severe CRS Management

1. Verify diagnosis - confirm cardinal symptoms (nasal obstruction, drainage, facial pain/pressure, smell loss) present for ≥12 weeks with objective findings 1, 2

2. Determine subtype:

   • With nasal polyps → Consider biologics if Type-2 inflammation, or surgery if polyps with bony erosion/eosinophilic mucin/fungal balls
   • Without nasal polyps → Medical therapy (INCS, saline rinses); consider macrolides for non-Type-2 endotypes 8

3. Assess for purulent discharge:

   • Present → Antibiotics appropriate
   • Absent → Do NOT prescribe antibiotics 1

4. Evaluate response to appropriate medical therapy:

   • Adequate response → Continue medical management
   • Inadequate response → Proceed to surgery or biologics based on subtype

5. Special populations:

   • AERD/NERD → Consider aspirin desensitization after aspirin therapy (ATAD) 3, 8
   • Comorbid asthma/atopic disease → Refer for biologic consideration 2

Common Pitfalls to Avoid

• Do not require arbitrary "maximal medical therapy" duration before considering surgery - this delays effective treatment and may cause harm 1
• Do not prescribe antibiotics without purulent discharge - this is explicitly contraindicated 1
• Do not perform simple balloon dilation for disease with polyps, osteitis, or fungal involvement - full surgical exposure is required 1
• Do not assume biologics work for all CRS - they are most effective for Type-2 CRSwNP, not CRS without polyps 3, 7